ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Biogen still had a top drug candidate.

<< Previous

Bullboard Posts

Next >>

Comment by M101on Mar 10, 2021 12:10pm

128 Views

Post# 32763155

RE:RE:RE:Biogen still had a top drug candidate.

Enjoyed the wretch, thanks. Now I'm up to date on what to think and when to think it, as are all potential pharma investors who will never hear about PMN.
It's no wonder our consutants have given up on thier overpaid jobs, except for the fees.

<< Previous

Bullboard Posts

Next >>

Cross border trading in Canada and Australia